Table 5 Adjusted odds of remaining in the study at M6 by variables found to be significant in univariate regression analysis
Significant variables | Multivariate regression analysis | ||
|---|---|---|---|
AORa | 95% CIb | P | |
Use of opioid | |||
  N | — | — |  |
  Y | 0.62 | 0.46, 0.85 | 0.003 |
Use of antidepressant | Â | Â | Â |
  N | — | — |  |
  Y | 1.42 | 0.98, 2.07 | 0.061 |
Use of anti-seizure | |||
  N | — | — |  |
  Y | 1.91 | 1.30, 2.81 |  < 0.001 |
WHOQOL—psychological (baseline) | |||
  < 54 | — | — |  |
  ≥ 54 | 1.43 | 1.08, 1.90 | 0.013 |
Preferred type of cannabis | |||
  CBD | — | — |  |
  THC | 0.87 | 0.59, 1.27 | 0.5 |
  No preference | 1.16 | 0.82, 1.63 | 0.4 |
Primary method of use | |||
  Inhaled | — | — |  |
  Orally ingested | 0.87 | 0.64, 1.19 | 0.4 |
Enrollment period | |||
  Enrolled prior to 17 April 2018 (M6 would be pre-legalization) | — | — |  |
  Enrolled between 17 April and 15 July 2018 (M6 would be post-legalization) | 0.28 | 0.18, 0.41 |  < 0.001 |